US company PRA International has entered into a strategic collaboration with two contract research organizations (CROs) in Southeast Asia in order to tap the fast-growing clinical research market in the region.
In the future, drug firms will expect Asian contract research
organizations (CRO) to offer improved discovery, development and
management capabilities, according to Commonwealth Biotechnologies
(CBI) CEO Paul D'Sylva.